Biotech and Pharmaceutical Companies Segment, by End User to Account Largest Share in Microbiology CRO Services Market during 2023-2031

According to our new research study on "Microbiology CRO Services Market Forecast to 2031 - Global Analysis - by Service Type, Application, Microorganisms, and End User," the market was valued at US$ 5.52 billion in 2023 and is expected to reach US$ 11.51 billion by 2031; it is expected to register a CAGR of 9.6% from 2023 to 2031. The microbiology CRO services market report highlights the key factors driving the microbiology CRO services market growth and prominent players with their developments in the market.

The microbiology CRO services market analysis has been carried out by considering the following segments: service type, application, microorganisms, end user, and geography. The market, based on application, is segmented into clinical, medical device, and others. The clinical segment held the largest share of the market in 2023; it is also expected to record the highest CAGR from 2023 to 2031.

The microbiology CRO services market, based on service type, is segmented into assay development, custom viral stock production, microbial testing, and others. The microbial testing segment held the largest share of the market in 2023.

In terms of microorganisms, the microbiology CRO services market is segmented into bacteria, fungi, viruses, and parasites. The bacteria segment held the largest share of the market in 2023.

Based on end user, the microbiology CRO services market is segmented into biotech and pharmaceutical companies, medical device companies, and others. The biotech and pharmaceutical companies segment held the largest share of the market in 2023. The demand for specialized expertise in niche therapeutic areas such as oncology, rare diseases, immunology, and personalized medicine is growing. Pharmaceutical and biotechnology companies seek CROs showcasing knowledge and experience in specific areas to support their research and development efforts. These companies have started to prefer small to medium-sized CROs for their clinical development requirements as they are beginning to adopt a more agile and innovative business model. By outsourcing research activities, companies can save time and costs by not investing in research infrastructure and workforce.

In a few cases, CROs may even take the lead in innovation by establishing early chemistry and biology entry points into diseases and then seek collaboration with pharmaceutical companies. In September 2023, Cerba HealthCare acquired CIRION BioPharma Research to enhance its bioanalytical capabilities for clinical trials. This strengthened the company's expertise in Pharmacokinetic/Pharmacodynamic (PKPD) and Immunogenicity testing and expanded its presence in North America.

The scope of the microbiology CRO services market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the biggest contributor to the global microbiology CRO services market. The microbiology CRO market growth in the US is driven by the adoption of modern technologies by CROs, the surging number of clinical trials, and increasing investment in research and development by pharmaceutical and biotechnological companies. Also, strategic initiatives by market players play a significant role in supporting the microbiology CRO market growth. For instance, in February 2024, ICON plc acquired Clinical Research Management, Inc. (ClinicalRM). ClinicalRM offers comprehensive research solutions to various US government agencies.

Microbiologics, Melbec Microbiology, Emery Pharma, TheraIndx Lifesciences Pvt. Ltd., AVERIN BIOTECH, Statens Serum Institut, ImQuest BioScience, PACIFIC BIOLAB, Innovotech Inc, and BluTest Laboratories Ltd. are among the leading companies operating in the global microbiology CRO services market.

Companies operating in the microbiology CRO services market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the microbiology CRO services market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the developments made by the companies operating in microbiology CRO services market are as follows:

- In March 2024, Statens Serum Institut (SSI) collaborated with researchers from across Europe to create a vaccine that can guard against stomach ulcers. The partners in the collaboration are meeting at SSI to discuss their progress in 2024. The aim of Vax2muc is to develop advanced vaccines to prevent infections on the mucosal membrane in the intestinal tract, with the initial focus being on infections caused by the bacterium Helicobacter pylori, which leads to stomach ulcers.

- In October 2022, NAMSA, a leading MedTech CRO, acquired Perfectus Biomed Group, a UK-based laboratory specializing in customized microbiological services. This acquisition expanded NAMSA's presence in the UK and other regions, allowing it to serve clients in over 20 locations spanning the Americas, Asia, and Europe.


Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com